Tourmaline Bio Statistics

Total Valuation

Tourmaline Bio has a market cap or net worth of $410.34 million. The enterprise value is $207.58 million.

Market Cap	410.34M
Enterprise Value	207.58M

Important Dates

The next estimated earnings date is Wednesday, May 15, 2024, before market open.

Earnings Date	May 15, 2024
Ex-Dividend Date	n/a

Share Statistics

Tourmaline Bio has 25.65 million shares outstanding. The number of shares has increased by 441.28% in one year.

Shares Outstanding	25.65M
Shares Change (YoY)	+441.28%
Shares Change (QoQ)	+11.12%
Owned by Insiders (%)	15.51%
Owned by Institutions (%)	25.95%
Float	13.49M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	2.00
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 41.76, with a Debt / Equity ratio of 0.00.

Current Ratio	41.76
Quick Ratio	n/a
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -25.60% and return on invested capital (ROIC) is -22.10%.

Return on Equity (ROE)	-25.60%
Return on Assets (ROA)	-24.30%
Return on Capital (ROIC)	-22.10%
Revenue Per Employee	n/a
Profits Per Employee	-$957,364
Employee Count	44
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -38.70% in the last 52 weeks.

Beta (1Y)	n/a
52-Week Price Change	-38.70%
50-Day Moving Average	30.34
200-Day Moving Average	27.17
Relative Strength Index (RSI)	27.31
Average Volume (30 Days)	430,167

Short Selling Information

The latest short interest is 1.79 million, so 6.96% of the outstanding shares have been sold short.

Short Interest	1.79M
Short Previous Month	1.48M
Short % of Shares Out	6.96%
Short % of Float	13.24%
Short Ratio (days to cover)	2.04

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-45.41M
Pretax Income	-42.12M
Net Income	-42.12M
EBITDA	-41.97M
EBIT	-42.12M
Earnings Per Share (EPS)	-$8.87

Full Income Statement

Balance Sheet

The company has $203.18 million in cash and $415,000 in debt, giving a net cash position of $202.76 million or $7.91 per share.

Cash & Cash Equivalents	203.18M
Total Debt	415,000
Net Cash	202.76M
Net Cash Per Share	$7.91
Equity / Book Value	205.04M
Book Value Per Share	7.99
Working Capital	203.87M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$28.08 million and capital expenditures -$56,000, giving a free cash flow of -$28.14 million.

Operating Cash Flow	-28.08M
Capital Expenditures	-56,000
Free Cash Flow	-28.14M
FCF Per Share	-$5.93

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Tourmaline Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-441.28%
Shareholder Yield	-441.28%
Earnings Yield	-10.27%
FCF Yield	-6.86%

Dividend Details

Analyst Forecast

The average price target for Tourmaline Bio is $61.80, which is 286.25% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$61.80
Price Target Difference	286.25%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on October 20, 2023. It was a reverse split with a ratio of 1:10.

Last Split Date	Oct 20, 2023
Split Type	Reverse
Split Ratio	1:10

Scores

Altman Z-Score	n/a
Piotroski F-Score	3